These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 18056254)
1. CYP2D6-Mediated metabolism of a novel acyl coenzyme A:cholesterol acyltransferase inhibitor, pactimibe, and its unique plasma metabolite, R-125528. Kotsuma M; Tokui T; Ishizuka-Ozeki T; Honda T; Iwabuchi H; Murai T; Ikeda T; Saji H Drug Metab Dispos; 2008 Mar; 36(3):529-34. PubMed ID: 18056254 [TBL] [Abstract][Full Text] [Related]
2. Novel binding mode of the acidic CYP2D6 substrates pactimibe and its metabolite R-125528. Kotsuma M; Hanzawa H; Iwata Y; Takahashi K; Tokui T Drug Metab Dispos; 2008 Sep; 36(9):1938-43. PubMed ID: 18524873 [TBL] [Abstract][Full Text] [Related]
3. Effects of ketoconazole and quinidine on pharmacokinetics of pactimibe and its plasma metabolite, R-125528, in humans. Kotsuma M; Tokui T; Freudenthaler S; Nishimura K Drug Metab Dispos; 2008 Aug; 36(8):1505-11. PubMed ID: 18448569 [TBL] [Abstract][Full Text] [Related]
4. Effect of CYP2D6 polymorphism on pharmacokinetics of a novel ACAT inhibitor, pactimibe and its unique metabolite, R-125528. Kotsuma M; Tokui T; Freudenthaler S; Nishimura K Int J Clin Pharmacol Ther; 2008 Nov; 46(11):545-55. PubMed ID: 19000552 [TBL] [Abstract][Full Text] [Related]
5. Involvement of human cytochrome P450 2D6 in the bioactivation of acetaminophen. Dong H; Haining RL; Thummel KE; Rettie AE; Nelson SD Drug Metab Dispos; 2000 Dec; 28(12):1397-400. PubMed ID: 11095574 [TBL] [Abstract][Full Text] [Related]
6. Importance of acyl-coenzyme A:cholesterol acyltransferase 1/2 dual inhibition for anti-atherosclerotic potency of pactimibe. Kitayama K; Tanimoto T; Koga T; Terasaka N; Fujioka T; Inaba T Eur J Pharmacol; 2006 Jul; 540(1-3):121-30. PubMed ID: 16730694 [TBL] [Abstract][Full Text] [Related]
7. Cytochrome P4502D6 catalyzes the O-demethylation of the psychoactive alkaloid ibogaine to 12-hydroxyibogamine. Obach RS; Pablo J; Mash DC Drug Metab Dispos; 1998 Aug; 26(8):764-8. PubMed ID: 9698290 [TBL] [Abstract][Full Text] [Related]
8. Effect of sodium ozagrel on the activity of rat CYP2D6. Wu H; Yu W; Huang L; Wang J; Tang X; Yang W; Liu Y; Yu H; Zhu D Eur J Pharmacol; 2007 Nov; 573(1-3):55-9. PubMed ID: 17651725 [TBL] [Abstract][Full Text] [Related]
9. The use of 3-[2-(N,N-diethyl-N-methylammonium)ethyl]-7-methoxy-4-methylcoumarin (AMMC) as a specific CYP2D6 probe in human liver microsomes. Chauret N; Dobbs B; Lackman RL; Bateman K; Nicoll-Griffith DA; Stresser DM; Ackermann JM; Turner SD; Miller VP; Crespi CL Drug Metab Dispos; 2001 Sep; 29(9):1196-200. PubMed ID: 11502727 [TBL] [Abstract][Full Text] [Related]
11. Comparative aromatic hydroxylation and N-demethylation of MPTP neurotoxin and its analogs, N-methylated beta-carboline and isoquinoline alkaloids, by human cytochrome P450 2D6. Herraiz T; Guillén H; Arán VJ; Idle JR; Gonzalez FJ Toxicol Appl Pharmacol; 2006 Nov; 216(3):387-98. PubMed ID: 16870220 [TBL] [Abstract][Full Text] [Related]
12. Two novel CYP2D6*10 haplotypes as possible causes of a poor metabolic phenotype in Japanese. Matsunaga M; Yamazaki H; Kiyotani K; Iwano S; Saruwatari J; Nakagawa K; Soyama A; Ozawa S; Sawada J; Kashiyama E; Kinoshita M; Kamataki T Drug Metab Dispos; 2009 Apr; 37(4):699-701. PubMed ID: 19158312 [TBL] [Abstract][Full Text] [Related]
13. Mechanism-based inactivation of CYP2D6 by methylenedioxymethamphetamine. Heydari A; Yeo KR; Lennard MS; Ellis SW; Tucker GT; Rostami-Hodjegan A Drug Metab Dispos; 2004 Nov; 32(11):1213-7. PubMed ID: 15328252 [TBL] [Abstract][Full Text] [Related]
14. Tryptamine: a possible endogenous substrate for CYP2D6. Martínez C; Agúndez JA; Gervasini G; Martín R; Benítez J Pharmacogenetics; 1997 Apr; 7(2):85-93. PubMed ID: 9170145 [TBL] [Abstract][Full Text] [Related]
15. In-vitro metabolism of YM17E, an inhibitor of acyl coenzyme A:cholesterol acyltransferase, by liver microsomes in man. Uchida T; Watanabe T; Van Hoogdalem EJ; Higuchi S J Pharm Pharmacol; 1996 Oct; 48(10):1049-56. PubMed ID: 8953507 [TBL] [Abstract][Full Text] [Related]
16. Characterization of dextromethorphan O- and N-demethylation catalyzed by highly purified recombinant human CYP2D6. Yu A; Dong H; Lang D; Haining RL Drug Metab Dispos; 2001 Nov; 29(11):1362-5. PubMed ID: 11602510 [TBL] [Abstract][Full Text] [Related]
17. Multiple mechanisms of hypocholesterolemic action of pactimibe, a novel acyl-coenzyme A:cholesterol acyltransferase inhibitor. Kitayama K; Koga T; Inaba T; Fujioka T Eur J Pharmacol; 2006 Aug; 543(1-3):123-32. PubMed ID: 16814766 [TBL] [Abstract][Full Text] [Related]
18. In vitro metabolism of BYZX in human liver microsomes and the structural elucidation of metabolite by liquid chromatography-mass spectrometry method. Xia ZL; Ying JY; Sheng R; Zeng S; Hu YZ; Yao TW J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Oct; 857(2):266-74. PubMed ID: 17709305 [TBL] [Abstract][Full Text] [Related]
19. Cyp2D6 catalyzes 5-hydroxylation of 1-(2-pyrimidinyl)-piperazine, an active metabolite of several psychoactive drugs, in human liver microsomes. Raghavan N; Zhang D; Zhu M; Zeng J; Christopher L Drug Metab Dispos; 2005 Feb; 33(2):203-8. PubMed ID: 15507542 [TBL] [Abstract][Full Text] [Related]
20. CYP2D6.10 present in human liver microsomes shows low catalytic activity and thermal stability. Nakamura K; Ariyoshi N; Yokoi T; Ohgiya S; Chida M; Nagashima K; Inoue K; Kodama T; Shimada N; Kamataki T Biochem Biophys Res Commun; 2002 May; 293(3):969-73. PubMed ID: 12051754 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]